Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A compound of formula



(I),

including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein

X is N or CH;

R^1 is C_{1-6}alkyl, NR^6R^7, OR^7 or SR^7;

in case X is N then R^2 is hydrogen, C_{1-6}alkyl, C_{1-6}alkyloxy or C_{1-6}alkylthio;

in case X is CH then R^2 is C_{1-6}alkyl, C_{1-6}alkyloxy or C_{1-6}alkylthio;

R^3 is Ar^1 or Het^1;

R^4 and R^5 are each independently selected from hydrogen, halo, C_{1-6}alkyl, C_{1-6}alkyloxy, trifluoromethyl, cyano, nitro, amino, and mono- or di(C_{1-6}alkyl)amino;

R^6 is hydrogen, C_{1-8}alkyl, mono- or di(C_{3-6}cycloalkyl)methyl, C_{3-6}cycloalkyl, C_{3-6}alkenyl, hydroxyC_{1-6}alkyl, C_{1-6}alkylcarbonyloxyC_{1-6}alkyl or C_{1-6}alkyloxyC_{1-6}alkyl;

R^7 is C_{1-8}alkyl, mono- or di(C_{3-6}cycloalkyl)methyl, Ar^2CH^2, C_{1-6}alkyloxy-C_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{3-6}alkenyl, thienylmethyl, furanylmethyl, C_{1-6}alkylthioC_{1-6}alkyl, mono- or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, di(C_{1-6}alkyl)amino, C_{1-6}alkylcarbonylC_{1-6}alkyl;

or R^6 and R^7 taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C_{1-6}alkyl or C_{1-6}alkyloxyC_{1-6}alkyl; and

Ar^1 is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C_{1-6}alkyl, trifluoromethyl, hydroxy, cyano, C_{1-6}alkyloxy, benzyloxy, C_{1-6}alkylthio, nitro, amino and mono- or di(C_{1-6}alkyl)amino;

Het^1 is pyridinyl; pyridinyl substituted with 1, 2 or 3 substituents each independently selected from halo, C_{1-6}alkyl, trifluoromethyl, hydroxy, cyano, C_{1-6}alkyloxy, benzyloxy, C_{1-6}alkylthio, nitro, amino, and mono- or di(C_{1-6}alkyl)amino; and

Ar^2 is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C_{1-6}alkyl, C_{1-6}alkyloxy, di(C_{1-6}alkyl)aminoC_{1-6}alkyl, trifluoromethyl;

with the proviso that 2,4-dimethyl-8-(2-nitrophenyl)-quinoline is not included.

2. (Currently Amended) A compound according to claim 1 wherein R^1 is OR^7 or SR^7 and R^7 is C_{1-6}alkyl; or R^1 is NR^6R^7 and R^6 is hydrogen or C_{1-6}alkyl, and R^7 is C_{1-6}alkyl or C_{3-6}cycloalkylmethyl; R^2 is C_{1-6}alkyl; R^3 is a phenyl substituted with 1, 2 or 3 substituents each independently selected from C_{1-6}alkyl, C_{1-6}alkyloxy or halo, or R^3 is a pyridinyl substituted with 1, 2 or 3 substituents each independently selected from C_{1-6}alkyl or di(C_{1-6}alkyl)amino; and R^4 ~~or~~ and R^5 are each independently selected from hydrogen or C_{1-6}alkyl.

3. (Previously Presented) A compound according to claim 1 wherein R^1 is NR^6R^7 wherein R^6 is C_{2-4}alkyl and R^7 is C_{2-4}alkyl or cyclopropylmethyl; R^2 is C_{1-2}alkyl; R^3 is phenyl substituted with 1, 2 or 3 substituents each independently selected from hydrogen, halo or C_{1-6}alkyl.

4. (Previously Presented) A compound according to claim 1 wherein R^1 is NR^6R^7 wherein R^6 is C_{3-4}alkyl and R^7 is C_{3-4}alkyl or cyclopropylmethyl; R^2 is methyl; R^3 is 3-pyridinyl substituted on the 4- and/or 6-position with methyl or dimethylamino.

5. (Canceled)

6. (Previously Presented) A composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as claimed in claim 1.

7. (Previously Presented) A process for preparing a composition as claimed in claim 6 wherein a therapeutically effective amount of a compound as claimed in claim 1 is intimately mixed with a pharmaceutically acceptable carrier.

8.-12. (Canceled)

13. (Previously Presented) A method of antagonizing a CRF receptor in a warm-blooded animal, comprising administering to the animal an effective amount of a compound of claim 1.

14. (Previously Presented) A method of treating a disorder manifesting hypersecretion of CRF in a warm-blooded animal, comprising administering to the animal an effective amount of a compound of claim 1.

15. (Currently Amended) The method of claim 14 wherein the disorder is selected from depression, an anxiety-related disorder, a feeding disorder, stress-induced immune suppression, stroke, Cushing's disease, infantile spasms, epilepsy, seizure, and an inflammatory condition.

16. (Original) The method of claim 15 wherein the feeding disorder is anorexia nervosa, bulimia or irritable bowel syndrome.